<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25394057</article-id><article-id pub-id-type="pmc">4224859</article-id><article-id pub-id-type="publisher-id">19550</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19550</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P018</subject></subj-group></article-categories><title-group><article-title>Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ram&#x000f3;n Santos</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="AF0001_19550">1</xref></contrib><contrib contrib-type="author"><name><surname>Saumoy</surname><given-names>Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="AF0002_19550">2</xref></contrib><contrib contrib-type="author"><name><surname>Curran</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="AF0003_19550">3</xref></contrib><contrib contrib-type="author"><name><surname>Bravo</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="AF0001_19550">1</xref></contrib><contrib contrib-type="author"><name><surname>Navarro</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="AF0003_19550">3</xref></contrib><contrib contrib-type="author"><name><surname>Estany</surname><given-names>Carla</given-names></name><xref ref-type="aff" rid="AF0001_19550">1</xref></contrib><contrib contrib-type="author"><name><surname>Podzamczer</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="AF0002_19550">2</xref></contrib><contrib contrib-type="author"><name><surname>Ribera</surname><given-names>Esteban</given-names></name><xref ref-type="aff" rid="AF0003_19550">3</xref></contrib><contrib contrib-type="author"><name><surname>Negredo</surname><given-names>Eugenia</given-names></name><xref ref-type="aff" rid="AF0004_19550">4</xref></contrib><contrib contrib-type="author"><name><surname>Clotet</surname><given-names>Bonaventura</given-names></name><xref ref-type="aff" rid="AF0005_19550">5</xref></contrib><contrib contrib-type="author"><name><surname>Paredes</surname><given-names>Roger</given-names></name><xref ref-type="aff" rid="AF0005_19550">5</xref></contrib></contrib-group><aff id="AF0001_19550"><label>1</label>Internal Medicine Department, Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain</aff><aff id="AF0002_19550"><label>2</label>HIV Unit, Infectious Disease Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain</aff><aff id="AF0003_19550"><label>3</label>Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Universitat Aut&#x000f2;noma de Barcelona, Barcelona, Spain</aff><aff id="AF0004_19550"><label>4</label>Lluita contra la SIDA Foundation, Hospital Universitari Germas Trias i Pujol, Internal Medicine Department, Universitat de Vic, Barcelona, Spain</aff><aff id="AF0005_19550"><label>5</label>Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, IrsiCaixa Foundation, Universitat de Vic, Barcelona, Spain</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19550</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Ram&#x000f3;n Santos J et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19550"><title>Introduction</title><p>Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [<xref rid="CIT0001_19550" ref-type="bibr">1</xref>&#x02013;<xref rid="CIT0003_19550" ref-type="bibr">3</xref>]
It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are due to the addition or removal of other offending agents or other reasons.</p></sec><sec id="st2_19550"><title>Materials and Methods</title><p>This was a randomized, crossover, double-blind, placebo-controlled clinical trial (NCT 01458977). Subjects with HIV-1 RNA &#x0003c;50 copies/mL during at least 6 months on stable DRV/r (800/100 mg QD) or LPV/r (400/100 mg BID) monotherapy, with confirmed fasting total cholesterol &#x02265;200 or LDL-cholesterol &#x02265;130 mg/dL and not taking lipid-lowering drugs were randomized to (A) adding TDF/FTCduring 12 weeks followed by 24 weeks without TDF/FTC, or (B) continuing without TDF/FTC for 12 weeks, adding TDF/FTC for 12 weeks and then withdrawing TDF/FTC for 12 additional weeks. Randomization was stratified by DRV/r or LPV/r use at study entry. All subjects received a specific dietary counselling. Primary endpoints were changes in median fasting total, LDL and HDL-cholesterol 12 weeks after TDF/FTC addition. Analyses were performed by ITT.</p></sec><sec id="st3_19550"><title>Results</title><p>46 subjects with a median age of 43 (40&#x02013;48) years were enrolled in the study: 70% were male, 56% received DRV/r and 44% LPV/r. One subject withdrew the study voluntarily at week 4 and another one interrupted due to diarrhoea at week 24. Treatment with TDF/FTC decreased total, LDL and HDL-cholesterol from 235.9 to 204.9 (p&#x0003c;0.001), 154.7 to 127.6 (p&#x0003c;0.001) and 50.3 to 44.5 mg/dL (p&#x0003c;0.001), respectively. In comparison, total, LDL and HDL-cholesterol levels remained stable during placebo exposure. Week 12 total cholesterol (p&#x0003c;0.001), LDL-cholesterol (p&#x0003c;0.001) and HDL-cholesterol (p=0.011) levels were significantly lower in TDF/FTC versus placebo. Treatment with TDF/FTC reduced the fraction of subjects with abnormal fasting total-cholesterol (&#x02265;200 mg/dL) from 86.7% to 56.8% (p=0.001) and LDL-cholesterol (&#x02265;130 mg/dL) from 87.8% to 43.9% (p&#x0003c;0.001), which was not observed with placebo. There were no virological failures, and CD4 and triglyceride levels remained stable regardless of exposure.</p></sec><sec id="st4_19550"><title>Conclusion</title><p>Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF.</p></sec></abstract></article-meta></front><back><ref-list><title>References</title><ref id="CIT0001_19550"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananrowanich</surname><given-names>J</given-names></name><name><surname>Nuesch</surname><given-names>R</given-names></name><name><surname>Cote</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine: a Staccato trial substudy</article-title><source>J Antimicrob Chemoter</source><year>2008</year><volume>61</volume><fpage>1340</fpage><lpage>43</lpage></element-citation></ref><ref id="CIT0002_19550"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llibre</surname><given-names>JM</given-names></name><name><surname>Domingo</surname><given-names>P</given-names></name><name><surname>Palacios</surname><given-names>R</given-names></name><etal/></person-group><article-title>Sustained improvement of dyslipidemia in HAART-treated patients replacing stavudine with tenofovir</article-title><source>AIDS</source><year>2006</year><volume>20</volume><fpage>1407</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16791015</pub-id></element-citation></ref><ref id="CIT0003_19550"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>R</given-names></name><name><surname>Rivero</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>I</given-names></name><etal/></person-group><article-title>Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine</article-title><source>HIV Clin Trials</source><year>2010 Mar&#x02013;Apr</year><volume>11</volume><issue>2</issue><fpage>118</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">20542848</pub-id></element-citation></ref></ref-list></back></article>